Hepatitis C Drugs Market Research Report Information, By Drug Class (Anti-Viral, Immuno-modulators and others), By Medicine System (Allopathic, Alternative and Others), By Route of Administration (Oral, Injectable and others) and By End User (Hospitals and Private) - Forecast Till 2032

1 Introduction

1.1 Definition

1.2 Scope of Study

1.3 Research Objective

1.4 Assumptions & Limitations

1.5 Market Structure

2 Research Methodology

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research

3 Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

3.5 Macroeconomic Indicators

4 Market Factor Analysis

4.1 Porter’s five forces model

4.1.1 Bargaining Power of suppliers

4.1.2 Bargaining Power of Customer

4.1.3 Intensity of Competitor’s

4.1.4 Threat of New Entrants

5 Global Hepatitis C Drugs market, by Drug Class

5.1 Introduction

5.2 Anti-Viral

5.3 Immuno-modulators

5.4 Others

6 Global Hepatitis C Drugs Market, By Medicine System

6.1 Introduction

6.2 Allopathic

6.3 Alternative

6.4 Others

7 Global Hepatitis C Drugs Market, By Route of Administration

7.1 Introduction

7.2 Oral

7.3 Injectable

7.4 Others

8 Global Hepatitis C Drugs Market, By End User

8.1 Introduction

8.2 Hospitals

8.3 Private

9 Global Hepatitis C Drugs market, by Regions

9.1 Introduction

9.1.1 Americas

9.1.1.1 North America

9.1.1.2 South America

9.1.2 Europe

9.1.2.1 Germany

9.1.2.2 France

9.1.2.3 UK

9.1.2.4 Italy

9.1.2.5 Spain

9.1.2.6 Rest of Europe

9.1.3 Asia Pacific

9.1.3.1 Japan

9.1.3.2 China

9.1.3.3 India

9.1.3.4 Republic of Korea

9.1.3.5 Rest of Asia Pacific

9.1.4 Middle East & Africa

10 Company Landscape

10.1 Introduction

10.1.1 Mergers Acquisitions

10.1.2 Collaborations

10.1.3 Release/New Product Launches

10.1.4 Other (Expansion, Updates, Partnership)

11 Company Profile

11.1 Gilead sciences Inc.

11.1.1 Company Overview

11.1.2 Product/Business Segment Overview

11.1.3 Financials

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 Merck & Co.

11.2.1 Overview

11.2.2 Product/Business Segment Overview

11.2.3 Financials

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Novartis International AG

11.3.1 Overview

11.3.2 Product/Business Segment Overview

11.3.3 Financials

11.3.4 Key Developments

11.3.5 SWOT Analysis

11.4 Abbvie Inc

11.4.1 Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financials

11.4.4 Key Developments

11.4.5 SWOT Analysis

11.5 F. Hoffmann La Roche Ltd.

11.5.1 Overview

11.5.2 Product/Business Segment Overview

11.5.3 Financials

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Bristol-Myers Squibb

11.6.1 Overview

11.6.2 Product/Business Segment Overview

11.6.3 Financials

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Johnson & Johnson

11.7.1 Overview

11.7.2 Product/Business Segment Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.7 Glaxosmithkline plc

11.7.1 Overview

11.7.2 Product/Business Segment Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Others

11.8.1 Overview

11.8.2 Product/Business Segment Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

12 Others

13 Appendix

List of Tables

TABLE 1 GLOBAL HEPATITIS C DRUGS MARKET, 2020-2027 (USD MILLION)

TABLE 2 GLOBAL HEPATITIS C DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL HEPATITIS C DRUGS MARKET, BY MEDICINE SYSTEM, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL HEPATITIS C DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL HEPATITIS C DRUGS MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 6 GLOBAL HEPATITIS C DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION)

List of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 PORTERS FIVE FORCES MODEL

FIGURE 3 GLOBAL HEPATITIS C DRUGS MARKET, BY DRUG CLASS

FIGURE 4 GLOBAL HEPATITIS C DRUGS MARKET, BY MEDICINE SYSTEM

FIGURE 5 GLOBAL HEPATITIS C DRUGS MARKET, BY ROUTE OF ADMINISTRATION

FIGURE 6 GLOBAL HEPATITIS C DRUGS MARKET, BY END USER

FIGURE 7 GLOBAL HEPATITIS C DRUGS MARKET, BY REGION

FIGURE 8 GLOBAL HEPATITIS C DRUGS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)